Htopride in functional dyspepsia: results of two phase III mufticentre, randomised, double-blind, placebo-controlled trials

Talley, N. J.; Tack, J.; Ptak, T.; Gupta, R.; Giguère, M.
June 2008
Gut;Jun2008, Vol. 57 Issue 6, p470
Academic Journal
Background: Functional dyspepsia (FD) is a common disorder but there is currently little efficacious drug therapy. Itopride, a prokinetic approved in several countries, showed promising efficacy in FD in a phase lib trial. The aim of this study was to test the efficacy and safety of this drug in FD. Methods: Two similar placebo-controlled clinical trials were conducted (International and North America). Males and females, 18-65 years old, with a diagnosis of FD (Rome II) and the absence (by upper endoscopy) of any relevant structural disease were recruited. All were negative for Helicobacter pylori and, if present, heartburn could not exceed one episode per week. Following screening, patients were randomised to itopride 100 mg three times daily or identical placebo. The co-primary end points were: (1) global patient assessment (GPA) of efficacy; and (2) Leeds Dyspepsia Questionnaire (LDQ). Symptoms were evaluated at weeks 2, 4 and 8. Secondary measures of efficacy included Nepean Dyspepsia Index (NDI) quality of life. Results: The GPA responder rates at week 8 on itopride versus placebo were similar in both trials 145.2% vs 45.6% and 37:8 vs 35.4%, respectively; p = NS). A significant benefit of itopride over placebo was observed for the LDQ responders in the International (62% vs 52.7%, p = 0.04) but not the North American trial (46.9% vs 44.8%). The safety and tolerability profile were comparable with placebo, with the exception of prolactin elevations, which occurred more frequently on itopride (18/579) than placebo (1/591). Conclusion: In this population with FD, itopride did not show a difference in symptom response from placebo.


Related Articles

  • Esophageal Hypersensitivity May Be a Major Cause of Heartburn. Rodriguez-Stanley, Sheila; Robinson, Malcolm; Earnest, David L.; Greenwood-Van Meerveld, Beverley; Miner Jr., Philip B. // American Journal of Gastroenterology;Mar1999, Vol. 94 Issue 3, p628 

    OBJECTIVE: Little is known about esophageal nociceptive thresholds in chronic heartburn sufferers with normal clinical findings. The aim of this study was to evaluate and to characterize the pathogenesis of heartburn in subjects who chronically use antacids and had not sought medical attention....

  • Esomeprazole Versus Pantoprazole for Healing Erosive Oesophagitis. Včev, Aleksandar; Begić, Ivana; Ostojić, Rajko; Jurčić, Dragan; Božić, Dubravko; Soldo, Ivan; Gmajnić, Rudika; Kondža, Goran; Khaznadar, Eyad; Mićunović, Nikola // Collegium Antropologicum;Sep2006, Vol. 30 Issue 3, p519 

    The aim of this study was to compare the efficacy of esomeprazole and pantoprazole with regard to healing and relief from gastroesophageal reflux disease-related symptoms. I this multicentre, randomized, single-blind study 180 patients (ITT population) diagnosed with endoscopically proven GERD...

  • Evaluation of the Patient with Dyspepsia. Smucny, John // Journal of Family Practice;Jun2001, Vol. 50 Issue 6, p538 

    The article discusses the evaluation of patients with dyspepsia. It informs that dyspepsia is chronic or recurrent pain or discomfort that is centered in the upper abdomen. Symptoms of the disease includes early satiety, fullness, bloating, and nausea. Details concerning the differential...

  • Prevalence of acid reflux in functional dyspepsia and its association with symptom profile. Tack, J.; Caenepeel, P.; Arts, J.; Lee, K.-J.; Sifrim, D.; Janssens, J. // Gut;Oct2005, Vol. 54 Issue 10, p1370 

    Aim: A subset of functional dyspepsia patients respond to acid suppressive therapy, but the prevalence of non-erosive reflux disease in functional dyspepsia and its relevance to symptoms have never been established. The aim of the present study was to study 24 hour pH monitoring in consecutive...

  • Evaluation of Chronic Gastrointestinal Symptoms following Persian Gulf War Exposure. Koch, Timothy R.; Emory, Theresa S. // Military Medicine;Aug2005, Vol. 170 Issue 8, p696 

    This was a prospective study performed in a Department of Veterans Affairs Medical Center. The aim of this study was to use endoscopic and histological examinations to determine the potential diagnostic origins of chronic gastrointestinal symptoms among patients who were part of the deployment...

  • Rabeprazole 20 mg for erosive esophagitis-associated symptoms in a large, community-based study: additional results. Cutler, Alan; Robinson, Malcolm; Murthy, Anita; DeLemos, Byron // Digestive Diseases & Sciences;Feb2010, Vol. 55 Issue 2, p338 

    Purpose: To provide additional efficacy data in patients treated with rabeprazole through week 4, and to validate sustained relief of gastroesophageal reflux disease symptoms through week 8 as well as to further analyze rabeprazole safety in patients with wide-ranging demographic...

  • Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. Savarino, E.; Pohl, D.; Zentilin, P.; Dulbecco, P.; Sammito, G.; Sconfienza, L.; Vigneri, S.; Camerini, G.; Tutuian, R.; Savarino, V. // Gut;Sep2009, Vol. 58 Issue 9, p1185 

    Introduction: Functional dyspepsia and non-erosive reflux disease (NERD) are prevalent gastrointestinal conditions with accumulating evidence regarding an overlap between the two. Still, patients with NERD represent a very heterogeneous group and limited data on dyspeptic symptoms in various...

  • Quality of Life in Patients With Endoscopy- Negative Heartburn: Reliability and Sensitivity of Disease-Specific Instruments. Talley, Nicholas J.; Fullerton, Steve; Junghard, Ola; Wiklund, Ingela // American Journal of Gastroenterology;Jul2001, Vol. 96 Issue 7, p1998 

    OBJECTIVES: Endoscopy-negative gastroesophageal reflux disease (GERD) lacks objective markers of disease severity. Evaluation of therapies for GERD must therefore rely on subjective measures, including patient self-report questionnaires, to measure the clinical effectiveness of therapeutic...

  • Review: Proton-pump inhibitor therapy reduces symptoms in nonulcer dyspepsia better than placebo: COMMENTARY. Veldhuyzen Van Zanten, Sander J. // ACP Journal Club;May/Jun2005, Vol. 142 Issue 3, p74 

    This article reports that the diagnosis of nonulcer dyspepsia (NUD) requires a normal endoscopy result, but this is poorly handled in a study, which reported that proton-pump inhibitor therapy reduces symptoms in nonulcer dyspepsia better than placebo. Before having endoscopy, many patients take...


Read the Article


Sign out of this library

Other Topics